Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 4.64
SNSS's Cash to Debt is ranked higher than
64% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. SNSS: 4.64 )
SNSS' s 10-Year Cash to Debt Range
Min: 2.18   Max: No Debt
Current: 4.64

Equity to Asset 0.31
SNSS's Equity to Asset is ranked higher than
54% of the 1094 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SNSS: 0.31 )
SNSS' s 10-Year Equity to Asset Range
Min: -2.09   Max: 0.87
Current: 0.31

-2.09
0.87
F-Score: 3
Z-Score: -15.49
M-Score: -3.70
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -785.54
SNSS's Operating margin (%) is ranked higher than
58% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -96.70 vs. SNSS: -785.54 )
SNSS' s 10-Year Operating margin (%) Range
Min: -64863.64   Max: -169.03
Current: -785.54

-64863.64
-169.03
Net-margin (%) -749.95
SNSS's Net-margin (%) is ranked higher than
57% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. SNSS: -749.95 )
SNSS' s 10-Year Net-margin (%) Range
Min: -74506.06   Max: -166.44
Current: -749.95

-74506.06
-166.44
ROE (%) -406.94
SNSS's ROE (%) is ranked lower than
53% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. SNSS: -406.94 )
SNSS' s 10-Year ROE (%) Range
Min: -1198.61   Max: -57.33
Current: -406.94

-1198.61
-57.33
ROA (%) -81.95
SNSS's ROA (%) is ranked higher than
54% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. SNSS: -81.95 )
SNSS' s 10-Year ROA (%) Range
Min: -448.13   Max: -39.99
Current: -81.95

-448.13
-39.99
ROC (Joel Greenblatt) (%) -116090.21
SNSS's ROC (Joel Greenblatt) (%) is ranked lower than
56% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. SNSS: -116090.21 )
SNSS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -138593.85   Max: -460.2
Current: -116090.21

-138593.85
-460.2
Revenue Growth (3Y)(%) -6.50
SNSS's Revenue Growth (3Y)(%) is ranked higher than
72% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. SNSS: -6.50 )
SNSS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 74.5
Current: -6.5

0
74.5
EBITDA Growth (3Y)(%) 15.90
SNSS's EBITDA Growth (3Y)(%) is ranked higher than
86% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. SNSS: 15.90 )
SNSS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -59.5   Max: 15.9
Current: 15.9

-59.5
15.9
EPS Growth (3Y)(%) 18.70
SNSS's EPS Growth (3Y)(%) is ranked higher than
88% of the 803 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. SNSS: 18.70 )
SNSS' s 10-Year EPS Growth (3Y)(%) Range
Min: -60.4   Max: 20.5
Current: 18.7

-60.4
20.5
» SNSS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

SNSS Guru Trades in Q1 2014

Steven Cohen 502,900 sh (New)
Jim Simons 23,214 sh (New)
Jean-Marie Eveillard 219,557 sh (-8.50%)
» More
Q2 2014

SNSS Guru Trades in Q2 2014

Steven Cohen 468,500 sh (unchged)
Jim Simons 22,886 sh (-1.41%)
Jean-Marie Eveillard 200,000 sh (-8.91%)
» More
Q3 2014

SNSS Guru Trades in Q3 2014

Jean-Marie Eveillard Sold Out
Jim Simons Sold Out
Steven Cohen Sold Out
» More
Q4 2014

SNSS Guru Trades in Q4 2014

Paul Tudor Jones 17,516 sh (New)
Jean-Marie Eveillard 1,414,276 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with SNSS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 13.00
SNSS's P/B is ranked lower than
53% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. SNSS: 13.00 )
SNSS' s 10-Year P/B Range
Min: 1.01   Max: 297.5
Current: 13

1.01
297.5
P/S 28.86
SNSS's P/S is ranked higher than
56% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 36.81 vs. SNSS: 28.86 )
SNSS' s 10-Year P/S Range
Min: 0.9   Max: 157.25
Current: 28.86

0.9
157.25
Current Ratio 1.59
SNSS's Current Ratio is ranked higher than
55% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. SNSS: 1.59 )
SNSS' s 10-Year Current Ratio Range
Min: 1.19   Max: 7.2
Current: 1.59

1.19
7.2
Quick Ratio 1.59
SNSS's Quick Ratio is ranked higher than
58% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. SNSS: 1.59 )
SNSS' s 10-Year Quick Ratio Range
Min: 1.19   Max: 7.2
Current: 1.59

1.19
7.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.20
SNSS's Price/Net Cash is ranked higher than
71% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 103.40 vs. SNSS: 14.20 )
SNSS' s 10-Year Price/Net Cash Range
Min: 1.91   Max: 33.79
Current: 14.2

1.91
33.79
Price/Net Current Asset Value 14.20
SNSS's Price/Net Current Asset Value is ranked higher than
69% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 42.30 vs. SNSS: 14.20 )
SNSS' s 10-Year Price/Net Current Asset Value Range
Min: 1.86   Max: 18.26
Current: 14.2

1.86
18.26
Price/Tangible Book 12.80
SNSS's Price/Tangible Book is ranked higher than
53% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. SNSS: 12.80 )
SNSS' s 10-Year Price/Tangible Book Range
Min: 1.6   Max: 273.5
Current: 12.8

1.6
273.5
Price/Median PS Value 3.10
SNSS's Price/Median PS Value is ranked higher than
66% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. SNSS: 3.10 )
SNSS' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 5.53
Current: 3.1

0.1
5.53
Earnings Yield (Greenblatt) -30.40
SNSS's Earnings Yield (Greenblatt) is ranked lower than
63% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. SNSS: -30.40 )
SNSS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -31.8   Max: 16670.9
Current: -30.4

-31.8
16670.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:RYIN.Germany,
Sunesis Pharmaceuticals Inc was incorporated in the state of Delaware on February 10, 1998. It is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. It currently focuses on the development of vosaroxin for the treatment of acute myeloid leukemia, or AML. Vosaroxin is an anti-cancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. In October 2014, the Company announced the results of a Phase 3, multi-national, randomized, double-blind, placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML, or the VALOR trial. The VALOR trial, which enrolled 711 adult patients, was designed to evaluate the effect of vosaroxin in combination with cytarabine, most commonly used chemotherapy in AML, on overall survival as compared to placebo in combination with cytarabine, and was conducted at 124 study sites in the U.S., Canada, Europe, South Korea, Australia and New Zealand. It faces competition from many pharmaceutical, biopharmaceutical and biotechnology companies that are researching, developing and marketing products designed to address the treatment of cancer, including AML and ovarian cancer. In addition to regulations in the United States, the Company is subject to foreign regulations governing clinical trials and commercial sales and distribution of vosaroxin or its future drug candidates, if any.
» More Articles for SNSS

Headlines

Articles On GuruFocus.com
ciazek stock Mar 28 2015 
comment on SNSS Mar 02 2013 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 
Weekly CFO Buys Highlight: SNSS, INUV, CEP, CMTL, SURW Oct 09 2010 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 13 2010 
cooldecency99 note on SNSS May 01 2010 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Apr 29 2010 
Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCor Dec 15 2009 
Most Trade Guru Stocks: Citigroup Inc., Bank of America Corp., Alcoa Inc., Sunesis Pharmaceuticals Dec 12 2009 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 16 2009 

More From Other Websites
Biotech Stock Mailbag: Biogen's Alzheimer's Update, Celgene Patent Worries, Receptos, MannKind Apr 10 2015
Sunesis Pharmaceuticals Inc.'s CEO Daniel Swisher Interviewed by The Life Sciences Report Apr 02 2015
Esperion Therapeutics Inc (ESPR), Intercept Pharmaceuticals Inc (ICPT): Visium and OrbiMed’s... Mar 31 2015
SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Mar 23 2015
SUNESIS PHARMACEUTICALS INC Financials Mar 19 2015
SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Mar 12 2015
Sunesis Pharmaceuticals Inc Earnings Call scheduled for 11:00 am ET today Mar 12 2015
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2014 Financial Results and Recent... Mar 12 2015
Sunesis reports 4Q loss Mar 12 2015
Sunesis reports 4Q loss Mar 12 2015
Q4 2014 Sunesis Pharmaceuticals Inc Earnings Release - Before Market Open Mar 12 2015
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2014 Financial Results and Recent... Mar 12 2015
Sunesis to Host Conference Call on March 12th to Discuss Fourth Quarter and Full-Year 2014 Financial... Mar 05 2015
SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change... Mar 02 2015
Sunesis Announces Amendment to Loan Agreement Mar 02 2015
Sunesis Announces Amendment to Loan Agreement Mar 02 2015
Sunesis to Present at Upcoming Investor Conferences Feb 24 2015
Sunesis to Present at Upcoming Investor Conferences Feb 24 2015
Sunesis to Present at the 2015 RBC Capital Markets' Global Healthcare Conference Feb 18 2015
Sunesis to Present at the 2015 RBC Capital Markets' Global Healthcare Conference Feb 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK